P23002-25 Pre-Assessment - Medical Learning Institute Inc

Skip to content

Medical Learning Institute Inc

Home
Activities
- Upcoming Events
- On-Demand Activities
Educational Series
- Featured Educational Series
Accreditation
- About MLI Accreditation
About Us
Contact Us

Medical Learning Institute Inc

Home
Activities
- Upcoming Events
- On-Demand Activities
Educational Series
- Featured Educational Series
Accreditation
- About MLI Accreditation
About Us
Contact Us

Part 1 | Wednesday, July 31, 2024, Pre-Assessment

Please enable JavaScript in your browser to complete this form.

Please provide your National Provider Identifier (NPI) number

1. Which of the following comorbidities is most commonly experienced among patients with obesity? *

A. Non-alcoholic fatty liver disease
B. Obstructive sleep apnea
C. Hypertension
D. Type 2 Diabetes

2. Your 44-year-old patient with a BMI of 36 kg/m2 presents to the clinic for an annual visit. She has a history of dyslipidemia and hypertension. What % weight loss is needed to see a therapeutic benefit in her hypertension? *

A. At least 3%, with max benefit at >15%
B. At least 5%, with max benefit at >15%
C. At least 10%
D. At least 15%

3. Which of the following is true regarding the second-generation anti-obesity medications (AOMs) semaglutide and tirzepatide? *

A. ~5-8% weight loss in over half of patients with obesity as an adjuvant to lifestyle modifications
B. ≥15% weight loss in over half of patients with obesity as an adjuvant to lifestyle modifications
C. Both require daily subcutaneous administration
D. Both A and C are correct

Medical Learning Institute Inc
40946 US Highway 19N, #602
Tarpon Springs, FL, 34689
888.654.2631 (toll-free)
609.333.1693 (direct)

Scroll to Top